HOPE BIOSCIENCES, INC. announced that it has acquired exclusive and worldwide rights to develop and commercialize HOPE 777, a unique MERTK/AXL/pan-c-MET tyrosine kinase inhibitor through a licensing agreement with NeoPharm Co. Ltd. HOPE 777 has undergone extensive preclinical evaluation, and the data suggest that it has an impressive potency against the receptor tyrosine kinases MERTK, AXL, and pan-c-MET, key targets of tumor growth, chemotherapy resistance, epithelial-mesenchymal transition (EMT) behind cancer metastases, and tumor immune suppression.